Lung cancer is one of the leading causes of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancer cases. Despite recent advancements in treatment, including targeted therapies and chemotherapy, the overall prognosis for patients with advanced-stage NSCLC remains poor. However, the emergence of immunotherapy has brought new hope to the field of lung cancer treatment.